Eribulin in mTNBC Patients

N/ACompletedNCT04541420

Fudan University208 enrolled

Overview

To evaluate the efficacy and safety of Eribulin in patients with advanced breast cancer.

Study Type

OBSERVATIONAL

Enrollment

208

Conditions

Breast Cancer

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: 1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020. 3. Available medical history. Exclusion Criteria: 1\. Incomplete medical history.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: 6 weeks

Adverse events

Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.